Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;81(6):772-781.
doi: 10.1002/ana.24951. Epub 2017 Jun 5.

Chemotherapy-induced peripheral neuropathy: A current review

Nathan P Staff  1 , Anna Grisold  2 , Wolfgang Grisold  3 , Anthony J Windebank  1
Affiliations
Review

Chemotherapy-induced peripheral neuropathy: A current review

Nathan P Staff et al. Ann Neurol. 2017 Jun.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents. Ann Neurol 2017;81:772-781.

PubMed Disclaimer

Conflict of interest statement

POTENTIAL CONFLICTS OF INTEREST

None

Figures

Figure 1
Figure 1
Neurotoxic chemotherapeutic agents target multiple aspects of the sensory peripheral nerve.
See this image and copyright information in PMC

References

    1. Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract. 2012;2012:913848. - PMC - PubMed
    1. Brugnoletti F, Morris EB, Laningham FH, et al. Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. Pediatr Blood Cancer. 2009 Feb;52(2):293–5. - PMC - PubMed
    1. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology. 2011 May;12(5):431–40. - PubMed
    1. Briani C, Vitaliani R, Grisold W, et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology. 2011 Feb 22;76(8):705–10. - PubMed
    1. Stubgen JP. Lymphoma-associated dysimmune polyneuropathies. J Neurol Sci. 2015 Aug 15;355(1-2):25–36. - PubMed

MeSH terms

Substances